Evidence map›Paper›PMID 26701143›Full record

ArticleBiomaterials2016

Transforming growth factor-beta 1 delivery from microporous scaffolds decreases inflammation post-implant and enhances function of transplanted islets.

Jeffrey M H Liu, Jesse Zhang, Xiaomin Zhang, Kelan A Hlavaty, Christine F Ricci, Joshua N Leonard, Lonnie D Shea, R Michael Gower

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 119 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Cell-Inspired Biomaterials for Modulating Inflammation.Tissue engineering. Part B, Reviews · 2022
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Jeffrey M H LiuInterdisciplinary Biological Sciences Program, Northwestern University, Evanston, IL 60208, USA; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Jesse ZhangDepartment of Biomedical Engineering, Northwestern University, Evanston, IL 60208, USA.
Xiaomin ZhangDepartment of Surgery, Division of Transplantation, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Kelan A HlavatyDepartment of Biomedical Engineering, Northwestern University, Evanston, IL 60208, USA.
Christine F RicciDepartment of Chemical and Biological Engineering, Northwestern University, Evanston, IL 60208, USA.
Joshua N LeonardDepartment of Chemical and Biological Engineering, Northwestern University, Evanston, IL 60208, USA.
Lonnie D SheaDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: ldshea@umich.edu.
R Michael GowerDepartment of Chemical Engineering, University of South Carolina, Columbia, SC 29208, USA; Biomedical Engineering Program, University of South Carolina, Columbia, SC 29208, USA. Electronic address: gowerrm@mailbox.sc.edu.
Northwestern University · USUniversity of Michigan–Ann Arbor · USUniversity of South Carolina · US

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Daniela E Matei · 1993 to 2026
$153.9M
Targeting early ceramide elevation in pre-symptomatic eczemaP20GM103641 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI NAGARKATTI, PRAKASH S · 2012 to 2023
$20.7M
Developing Capacity to Evaluate Training Programs via Development of Human, Institutional and Social CapitalT32GM008449 · NIGMS · NORTHWESTERN UNIVERSITY · PI LEONARD, JOSHUA NATHANIEL · 1993 to 2023
$7.8M
Controlled Release Scaffolds for Nerve RegenerationR01EB005678 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ANDERSON, AILEEN J, SHEA, LONNIE D · 2007 to 2018
$6.0M
An in vivo metastasis sensorR01CA173745 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BACKMAN, VADIM, SHEA, LONNIE D · 2012 to 2016
$4.2M
Protein-Releasing Microporous Scaffolds for Cell Replacement TherapyR01EB009910 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUO, XUNRONG, SHEA, LONNIE D · 2010 to 2018
$3.5M
NCI NIH HHS CA060553NCI NIH HHS P30 CA060553NCI NIH HHS R01 CA173745NIBIB NIH HHS R01 EB005678NIBIB NIH HHS R01 EB009910NIGMS NIH HHS P20 GM103641NIGMS NIH HHS T32 GM008449
6 · The paper itself

Abstract

Biomaterial scaffolds are central to many regenerative strategies as they create a space for infiltration of host tissue and provide a platform to deliver growth factors and progenitor cells. However, biomaterial implantation results in an unavoidable inflammatory response, which can impair tissue regeneration and promote loss or dysfunction of transplanted cells. We investigated localized TGF-β1 delivery to modulate this immunological environment around scaffolds and transplanted cells. TGF-β1 was delivered from layered scaffolds, with protein entrapped within an inner layer and outer layers designed for cell seeding and host tissue integration. Scaffolds were implanted into the epididymal fat pad, a site frequently used for cell transplantation. Expression of cytokines TNF-α, IL-12, and MCP-1 were decreased by at least 40% for scaffolds releasing TGF-β1 relative to control scaffolds. This decrease in inflammatory cytokine production corresponded to a 60% decrease in leukocyte infiltration. Transplantation of islets into diabetic mice on TGF-β1 scaffolds significantly improved the ability of syngeneic islets to control blood glucose levels within the first week of transplant and delayed rejection of allogeneic islets. Together, these studies emphasize the ability of localized TGF-β1 delivery to modulate the immune response to biomaterial implants and enhance cell function in cell-based therapies.

Indexed as

AnimalsAnti-Inflammatory AgentsCells, CulturedChemokine CCL2Diabetes Mellitus, ExperimentalDrug Delivery SystemsImmunomodulationInterleukin-12Islets of Langerhans TransplantationMaleMiceMice, Inbred C57BLPorosityTissue ScaffoldsTransforming Growth Factor beta1Tumor Necrosis Factor-alphaAnti-Inflammatory AgentsChemokine CCL2Interleukin-12Transforming Growth Factor beta1Tumor Necrosis Factor-alphaImmunoengineeringImmunomodulationLeukocyteScaffoldTransplant

Identifiers

PMID26701143
PMCPMC4706476
OpenAlexW2187798079

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.